Rola leków inkretynowych w leczeniu cukrzycy typu 2

• Authors: Mizerski Grzegorz , Jaroszyński Andrzej
• Languages of publication: PL

Keywords

PL

cukrzyca typu 2; leczeni; inkretyny; gliptyny

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2012
• Issue: 4
• Pages: 596-600

Contributors

author

Mizerski Grzegorz

author

Jaroszyński Andrzej

References

• Holst JJ, Gromada 1. J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.Am J Physiol Endocrinol Metab 2004; 287: 199–206.
• Holst JJ. Glukagonopodobny peptyd 1: właściwości fizjologiczne i możliwości terapeutyczne. Current Opinion in Endocrinology and Diabetes (wyd. polskie) 2005: 4(1): 14–19.
• Irwin N, Flatt PR. Therapeutic potential for GIP receptor agonists and antagonists. Best Pract Res Clin Endocrinol Metab 2009; 23(4): 499–512.
• Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128 (2):117–124.
• Færch K, Waag A, Holst JJ, et al. Impaired fasting glycaemia and impaired glucose tolerance: similar impairment of pancreatic a and b cell function but differential role of incretin hormones and insulin action. Diabetologia 2008: 51: 853–861.
• Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122(2):531–544.
• Drucker DJ. The role of gut hormones in glucose homeostasis. JCI 2007; 117: 24–32.
• Meier JJ, Nauck MA. Is the dimished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta cell function? Diabetes 2010; 59: 1117–1125.
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52.
• Kołcz M, i wsp. Analogi GLP-1 u chorych na cukrzycę typu 2 – przegląd systematyczny. Medycyna Praktyczna 2012; 1(251): 74–81.
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.
• Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control oftype 2 diabetes. Regul Pept 2004; 117: 77–88.
• A. Hormony inkretynowe w leczeniu cukrzycy typu 2. Część II. Inkretyny – nowe możliwości farmakoterapii cukrzycy typu 2. Endokrynol Pol/Polish J Endocrinology 2008; 4(58): 322–329.
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diab Care 2005; 28: 1083–1091.
• Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317–327.
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372 (9645): 1240–1250.
• Buse JB, Rosenstock J, Seti G, et al. LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374(9683): 39–47. Epub 2009 Jun 8.
• European Medicines Agency. Charakterystyka produktu leczniczego Byetta, dostępna na stronie: http://www.ema.europa. eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf.
• European Medicines Agency. Charakterystyka produktu leczniczego Victoza, dostępna na stronie http://www.ema.europa. eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf.
• Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97: 6874–6879.
• Nagakura T, Yasuda N, Yamazaki K, et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001; 284: 501–506.
• Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 6825–6830.
• Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741–750.
• Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diab Obes Metab 2008; 18: 422–426.
• Pham DQ, Nogid A, Plakogiannis R. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. Am J Health Syst Pharm 2008; 65: 521–531.
• Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diab Res Clin Pract 2007; 76: 132–138.
• Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diab Care 2006; 29: 2632–2637.
• Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diab Care 2006; 29: 2638–2643.
• Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone:a randomized, double-blind, non-inferiority trial. Diab Obes Metab 2007; 9: 194–205.
• Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes:a 24-week, doubleblind, randomized trial. Diab Med 2008; 25: 435–441.
• Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagons levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078–2084.
• Mistry G, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48: 592–598.
• European Medicines Agency. Charakterystyka produktu leczniczego Onglyza, dostępna na stronie http://www.ema. europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf.
• European Medicines Agency. Charakterystyka produktu leczniczego Januvia, dostępna na stronie http://www.msd.pl/ media/chpl/lekarz/ChPLLeki/JANUVIA/10_11_26_Januvia_ChPL_WS-046.pdf.
• European Medicines Agency. Charakterystyka produktu leczniczego Galvus, dostępna na stronie http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf.
• Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54: 2988–2994